GrowthHormone Research Society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome.

ABSTRACT:

Context

Recombinant human GH (rhGH) therapy in Prader-Willi syndrome (PWS) has been used by the medical community and advocated by parental support groups since its approval in the United States in 2000 and in Europe in 2001. Its use in PWS represents a unique therapeutic challenge that includes treating individuals with cognitive disability, varied therapeutic goals that are not focused exclusively on increased height, and concerns about potential life-threatening adverse events.

Objective

The aim of the study was to formulate recommendations for the use of rhGH in children and adult patients with PWS.

Evidence

We performed a systematic review of the clinical evidence in the pediatric population, including randomized controlled trials, comparative observational studi

SUBMITTER: Deal CL 

PROVIDER: S-EPMC3789886 | biostudies-literature | 2013 Jun

REPOSITORIES: biostudies-literature